(NP -LCB-/-LRB- (NP Age-related/JJ changes/NNS) (PP in/IN (NP (NP (NP-COOD (NP glucocorticoid/NN) and/CC (NP mineralocorticoid/NN)) receptors/NNS) (PP in/IN (NP (NP lymphocytes/NNS) (PP of/IN (NP-COOD (NP healthy/JJ persons/NNS) and/CC (NP (NP patients/NNS) (PP with/IN (NP hypertension/NN))))))))) -RCB-/-RRB-)
(S (NP-SBJ It/PRP) (VP has/VBZ (VP been/VBN (VP found/VBN (SBAR that/IN (S (NP-SBJ (NP the/DT number/NN) (PP of/IN (NP glucocorticoid/NN receptors/NNS)) (PP in/IN (NP (NP lymphocytes/NNS) (PP of/IN (NP (NP the/DT peripheral/JJ blood/NN) (PP of/IN (NP healthy/JJ elderly/JJ subjects/NNS))))))) (VP increases/VBZ ,/, (SBAR while/IN (S (NP-SBJ (NP the/DT number/NN) (PP of/IN (NP mineralocorticoid/NN receptors/NNS))) (VP decreases/VBZ))))))))) ./.)
(S (S (NP-SBJ-20 (NP The/DT mechanisms/NNS) (PP of/IN (NP hormone-receptor/NN interactions/NNS)) (PP in/IN (NP hypertension/NN))) (VP are/VBP (VP activated/VBN (NP *-20/-NONE-))) :/:) (S (NP-SBJ (NP the/DT number/NN) (PP of/IN (NP (NP-COOD (NP glucocorticoid/NN) and/CC (NP mineralocorticoid/NN)) binding/NN sites/NNS))) (VP grows/VBZ (PP in/IN (NP hypertensive/JJ patients/NNS))) ./.))
(S (ADVP Still/RB) (NP-SBJ-21 (NP a/DT (ADJP more/RBR essential/JJ) rise/NN) (PP in/IN (NP (NP the/DT number/NN) (PP of/IN (NP receptors/NNS)))) (PP *ICH*-105/-NONE-)) (VP is/VBZ (VP observed/VBN (NP *-21/-NONE-) (PP in/IN (NP mid-age/JJ hypertensive/NN patients/NNS)) (PP-105 than/IN (FRAG (PP in/IN (NP elderly/JJ ones/NNS)))))) ./.)
